AN2 Therapeutics (NASDAQ:ANTX) is a biopharmaceutical company focused on developing treatments for patients with rare, chronic, and serious infectious diseases. With an emphasis on innovative research and drug development, their lead project involves advancing a novel therapy for the treatment of non-tuberculous mycobacterial (NTM) infections, a significant and growing global health concern. AN2 Therapeutics aims to address the unmet medical needs of patients suffering from these infections through rigorous clinical development programs and strategic collaborations. Their objective is to enhance quality of life for patients by providing effective and accessible treatments for complex infectious diseases that are often difficult to treat with existing medications.